Background
During the first wave of COVID-19 there was a relatively low burden of disease in many Sub-Saharan African (SSA) countries despite considerable SARS-CoV-2 transmission. Immune activation prior to pathogen challenge may protect against subsequent, unrelated infections. We hypothesized that female sex workers (FSWs) would experience frequent exposures to SARS-CoV-2 through social and physical contact early in the pandemic, and that pre-existing immune activation would protect against infection and/or symptomatic disease.
Methods
FSWs from the Sex Worker Outreach Program (SWOP) clinics in Nairobi, Kenya had pre-pandemic blood and other biological samples collected mid-2019 (pre-pandemic), with follow up samples collected approximately 1 year later. SARS-CoV-2 infection was defined by the presence of antibodies against >=2 of 3 SARS-CoV-2 antigens (RBD, Spike, N). Plasma levels of pro-inflammatory markers in pre-pandemic samples were quantified using the MSD V-PLEX proinflammatory panel 1. Immune activation was defined using a composite scoring system composed of the 7 pro-inflammatory markers: IL-1ß, IL-2, IL-6, IL-8, IL-12p70, IFN , and TNF. Cytokine levels were divided into quartiles and a score ranging from 1 (1st quartile) to 4 (4th quartile) was assigned to each marker and summed to generate the immune activation score. 100 cases who subsequently went on to acquire SARS-CoV-2, and 100 controls were matched 1 to 1 for age (±5 years), and visit date (±2 weeks).
Results
Pro-inflammatory cytokines were detected robustly in cryo-preserved plasma. There was no significant difference in immune activation score between cases and controls (mean, 17.42 vs. 17.53; p = 0.86); furthermore, levels of the 7 individual cytokines were not significantly different between cases and controls (p>0.05). When looking at symptoms after SARS-CoV-2 infection, there was no significant difference in immune activation score nor in the individual cytokines between symptomatic vs. asymptomatic cases (p>0.05).
Conclusions
Levels of preceding systemic immune activation, as defined by plasma inflammatory markers, did not predict SARS-CoV-2 infection nor symptomatic disease in those who did become infected. This suggests that the low burden of severe COVID-19 disease in many SSA countries was not due to increased immune activation in this region. Future studies should investigate the role of immune activation at mucosal infection sites more proximal to viral entry.